Wiskind provides cleanroom materials for China Sinovac Biotech Vaccine Laboratory

In late-stage clinical trials in Brazil, Sinovac Biotech's vaccine has shown 78% effectiveness in fighting COVID-19, and 100% can prevent severe illness.

China Sinovac Biotech cooperated with Butanta Research Institute, Brazil's largest vaccine manufacturer, to conduct Phase III clinical research in Brazil. The agency said on Thursday that among the volunteers vaccinated, there were no severe cases. Although the effectiveness of Sinovac Biotech CoronaVac vaccine is not more than 90% like Moderna, this vaccine is easier to transport and can be stored at normal refrigerator temperature.

In December 2020, Sinovac Biotech announced that it is expected to produce 300 million doses of vaccine in 2020 and increase its production capacity to 600 million doses per year. Sinovac Biotech built a factory in Beijing for the production of COVID-19 vaccine. At present, Sinovac Biotech's vaccine research and development laboratory in China is provided by Wiskind with cleanroom materials, using a total of 15,000 square meters of cleanroom panels.

In view of the particularity of the vaccine laboratory, and taking into account the strength and aesthetic performance of the required cleanroom panels, Wiskind provides MGO rock wool cleanroom panels, which have the advantages of drug resistance, corrosion resistance, and pollution resistance. It is a pharmaceutical experiment Ideal for room.

As a professional clean room enclosure system service provider, Wiskind has the world’s first cleanroom panels production line with independent knowledge products, which can produce a variety of core materials, and can be customized to meet the needs of different industries. It has been used in pharmaceuticals, food, electronics, and hospitals. Provide professional clean room panels and technical support services for hundreds of customers in many fields.